Pangea Oncology, the first laboratory accredited in Spain to perform liquid biopsy for cancer treatment Blog Post

Pangaea Oncology –located at the Dexeus University Hospital and associated company of PCB – has been the first laboratory to be accredited in Spain for the determination of oncological biomarkers in blood (liquid biopsy) by the norm UNE-EN ISO 15189. This laboratory has great experience in the field of oncology, and was the first to be accredite in 2009 for the analysis in tissue of mutations in genes related to tumor processes, specifically in lung cancer. The result of these analyzes allows to predict the response to certain drugs and to apply personalized medicine to patients.

 

Researchers from the URV, CIBERDEM and IRB Barcelona have developed a new technique to study the metabolism Blog Post

A group of researchers from IRB Barcelona at PCB, the URV and CIBERDEM have developed a new methodology that uses Nuclear Magnetic Resonance (NMR) to study cell metabolism. It is a tool that makes it possible to monitor metabolic fluxes and, in just 10 minutes, provide dynamic information about a considerable number of molecules. It may be able to be used in future applications to understand the reasons why some diseases develop.

 

El Parc Científic de Barcelona participa al YoMo amb múltiples propostes Blog Post

El Parc Científic de Barcelona (PCB) participa activament a la  primera edició del Youth Mobile Festival (YoMo) que avui obre les seves portes al recinte Montjuïc de Fira Barcelona, en el marc del Mobile World Congress. Durant quatre dies, el YoMo rebrà la visita de uns 20.000 escolars de Catalunya i Espanya, en una enorme exposició de ciència i tecnologia, amb espectacles de teatre en viu, tallers interactius i altres propostes per inspirar a milers de joves i apropar-los a les carreres professionals de l’ecosistema mòbil i STEAM (Science, Technology, Engineering, Arts and Mathematic).

 

How tumor cells hijack healthy cells to promote metastasis Blog Post

A team of researchers led by Xavier Trepat –ICREA research professor at the Institute for Bioengineering of Catalonia (IBEC) based at PCB– has identified a mechanism by which cancer cells manage to escape the tumor to promote metastasis. The study, which was published today and will be on the cover of the prestigious journal Nature Cell Biology (doi:10.1038/ncb3478), and has been supported by the Obra Social “la Caixa”, revealed that tumor cells can reprogramme their healthy neighbours, dragging them out of the tumor and into other tissues.

 

Cebiotex raises a € 1.8 million in second funding round Blog Post

Cebiotex –a spin-off of the Hospital Sant Joan de Déu in Barcelona (HSJD) and the Universitat Politècnica de Catalunya (UPC) based at the Barcelona Science Park (PCB)– has closed a funding round totaling € 1.8 million. that will allow the company to complete the regulatory pre-clinical phase of post-surgery cancer treatment for soft tissue sarcomas CEB-01. This is the first therapeutic indication developed by its innovative technology platform Cebiotex®, based on biomedical application of nanofibers for the local delivery of drugs (Local Drug Delivery System).

 

The V International Academic Symposium of IEB analyses the challenges of energy economics Blog Post

Yesterday, February 7, the V International Symposium of the Barcelona Institute of Economics (IEB) of the UB on the challenges in the energy sector took place at he Barcelona Science Park. The previous day, the Foundation for Energy and Environmental Sustainability (Funseam), which analyzes and shares the results of the research of the Chair of Energy Sustainability of the UB, had also organized its V International Symposium at PCB with the participation from public officers and businesspeople from the main firms of this sector. 

 

Researchers find a new key target for the treatment of prostate cancer Blog Post

A team led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) –at the Barcelona Science Park– and the Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau) shows for the first time, the three-dimensional structure of the homodimeric androgen receptor ligand-binding domain, a structure that eluded researchers for years. This new structure of the nuclear receptor allows explaining more than forty mutations related to prostate cancer, one of the most common worldwide and especially in Catalonia, as well as known developing disorders.